Skip to main content
. 2021 Mar 12;19(3):148. doi: 10.3390/md19030148

Figure 4.

Figure 4

LMF-HSFx attenuates the NAFLD-induced inflammation and modulate adipogenesis. The graph demonstrated the change from baseline of serum (A) IL-6, (B) IFN-γ, (C) adiponectin and (D) leptin of patients with LMF-HSFx or placebo treatment. Significant reduction of IL-6 and IFN-γ change was observed at 3rd and 6th month in LMF-HSFx group (*** p < 0.001, compared with placebo). The significant increasing of leptin was observed at 6th month in LMF-HSFx group (** p < 0.01, compared with placebo).